Lilly acquired Akouos for $12.50/share cash (~$487M) plus a CVR up to $3.00/share, total potential deal value ~$610M. The acquisition added Akouos's portfolio of AAV gene therapies for inner-ear conditions, with lead asset AK-OTOF for OTOF-mediated hearing loss. Closed December 1, 2022.